Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.35 |
| ▸ | EHMT2 | Q96KQ7 | 12/20 | 0.34 |
| ▸ | EHMT1 | Q9H9B1 | 7/20 | 0.34 |
| ▸ | PGK1 | P00558 | 2/20 | 0.34 |
| ▸ | KDM1A | O60341 | 5/20 | 0.34 |
| ▸ | RCOR1 | Q9UKL0 | 5/20 | 0.34 |
| ▸ | KMT5A | Q9NQR1 | 1/20 | 0.32 |
| ▸ | OGA | O60502 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.32 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2246222 | 0.94 | TLR7 (0.42) | TLR7EHMT2EHMT1PGK1KDM1A | |
| SCHEMBL2244462 | 0.90 | CA12 (0.33) | TLR7EHMT2EHMT1PGK1 | |
| SCHEMBL2249570 | 0.90 | TLR7 (0.34) | TLR7EHMT2EHMT1PGK1KDM1A | |
| SCHEMBL2246141 | 0.85 | ACP1 (0.36) | TLR7KMT5AACHETLR9 | |
| SCHEMBL2246009 | 0.85 | ACP1 (0.36) | TLR7KMT5AACHETLR9 | |
| SCHEMBL2243586 | 0.84 | TLR7 (0.37) | TLR7EHMT2EHMT1PGK1KDM1A | |
| SCHEMBL2250349 | 0.83 | USP2 (0.42) | BCHEACHE | |
| SCHEMBL2246216 | 0.82 | CA12 (0.48) | PGK1GRM1 | |
| SCHEMBL2243857 | 0.80 | USP2 (0.40) | BCHEACHE | |
| SCHEMBL2245311 | 0.80 | CA12 (0.34) | EHMT2EHMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989451-B2 | Tricyclic 1,2,4-triazine oxides and compositions for therapeutic use in cancer treatments | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-08-02 | — | — | US | claimed |
| EP-1866292-B1 | TRICYCLIC 1,2,4-TRIAZINE OXIDES AND COMPOSITIONS THEREFROM FOR THERAPEUTIC USE IN CANCER TREATMENTS | AUCKLAND UNISERVICES LTD (NZ) | 2010-12-15 | — | — | EP | claimed |
| US-20090186886-A1 | Tricyclic 1,2,4-Triazine Oxides and Compositions for Therapeutic Use in Cancer Treatments | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-07-23 | — | — | US | claimed |
| US-7989451-B2 | Tricyclic 1,2,4-triazine oxides and compositions for therapeutic use in cancer treatments | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-08-02 | — | — | US | disclosed |
| EP-1866292-B1 | TRICYCLIC 1,2,4-TRIAZINE OXIDES AND COMPOSITIONS THEREFROM FOR THERAPEUTIC USE IN CANCER TREATMENTS | AUCKLAND UNISERVICES LTD (NZ) | 2010-12-15 | — | — | EP | disclosed |
| US-20090186886-A1 | Tricyclic 1,2,4-Triazine Oxides and Compositions for Therapeutic Use in Cancer Treatments | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186886-A1 | Tricyclic 1,2,4-Triazine Oxides and Compositions for Therapeutic Use in Cancer Treatments | HIF1AN, HIF1A, HYOU1 | TLR7 3161/4885EHMT2 940/4885EHMT1 973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.